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Wild aquatic birds are a continuous source of inﬂuenza viruses and
provide a reservoir for each of the 16 known subtypes of hemagglutinin
(HA) and 9 subtypes of neuraminidase (NA) (Fouchier et al., 2005; Rohm
et al., 1996; Webster et al., 1992). The emergence or re-emergence of
highly pathogenic avian inﬂuenza (HPAI) viruses in domestic poultry and
the increasing numbers of direct transmission of avian viruses to humans
underscore the persistent threat to public health. Six fatal cases of human
infectionwith HPAI H5N1 viruswere ﬁrst reported during an outbreak in
1997 in Hong Kong (Claas et al., 1998; Subbarao et al., 1998). Since then,
repeated outbreaks of HPAI H5N1 virus have emerged and spread to
countries across Asia, Europe, the Middle East, Africa, and the Paciﬁc.
Human cases have increased with a high fatality rate of 60%, and some
H5N1 isolates shown resistance to the antiviral drugs amantadine and
rimantadine (Cheung et al., 2006; de Jong et al., 2005; Le et al., 2005).
Currently, H5N1, H7N2, H7N3, H7N7 and H9N2 avian origin inﬂuenzaviruseshavebeenshowntocausehuman infectionsonmultipleoccasions
(Fouchier et al., 2004; Peiris et al., 1999; Wong and Yuen, 2006). Most
recently, the 2009 outbreak of a new H1N1 virus illustrates how fast a
newpandemic virus can spread in the human population once it acquires
the ability to transmit among humans (Nava et al., 2009; Solovyov et al.,
2009). Vaccination is considered to be the most effective preventive
measure against potential epidemic and pandemic inﬂuenza viruses.
Among the licensed vaccine formulations, split and subunit vaccines
are most frequently used for immunization against the yearly inﬂuenza
epidemics (Nicholson et al., 1979; Wright et al., 1977). In preclinical
studies, two doses of inactivated split vaccine against H5 subtype
provided protection against lethal challenges with homologous or
heterologous H5N1 viruses in mice or ferrets (Govorkova et al., 2006;
Lipatov et al., 2006; Nicolson et al., 2005; Subbarao et al., 2003; Webby
et al., 2004). Phase I clinical trials indicate that inactivated split vaccines
are not optimally immunogenic (Nicholson et al., 2001) and require
multiple doses (Stephenson et al., 2003) or the inclusion of an adjuvant to
induce a protective immune response (Atmar et al., 2006; Bresson et al.,
2006; Hehme et al., 2002; Lin et al., 2006). A baculovirus-expressed
recombinant H5 protein or subvirion H5 inﬂuenza vaccine was poorly
immunogenic and two doses of 90 μg HA were required to develop a
desired antibody response to the vaccine (Treanor et al., 2006; Treanor
et al., 2001). Although live, attenuated virus vaccines are licensed in an
intranasal spray form, there are some challenges for developing an
effective and safe live attenuated vaccine against avian inﬂuenza viruses
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live vaccine virus with human inﬂuenza viruses.
The currently licensed inﬂuenza vaccines are produced in embryo-
nated hen eggs, and the manufacturing process usually takes approx-
imately 6 months when a new virus seed is required. If the pandemic
virus causes widespread morbidity and mortality in poultry, the supply
of embryonated eggs needed for producing seasonal and pandemic
vaccines at the same time might be signiﬁcantly compromised.
Therefore, developing an alternative vaccine production system not
reliant on egg substrates is highly desirable.
Most pandemic vaccine candidates such as inactivated split or live
attenuated virus contain a modiﬁed HA with a deletion of the multibasic
amino-acid motif that is involved in broadening the tropism and in
enhancing the virulence for HPAI viruses (Steinhauer, 1999). The effect of
the multibasic amino-acid motif on inducing protective immunity by
pandemic vaccines has not beenwell studied. Also,we do not understand
the basis for the low immunogenicity of split or subunit H5 vaccines in
naïve individuals. In addition, protective immune correlates, doses of
vaccines, and frequencies of vaccination required for inducing protection
against pandemic viruses are not well understood. Therefore, we
investigated some of these important issues in this study using the
novel vaccine platform of non-infectious inﬂuenza VLPs.
Our laboratory and others have developed H5 inﬂuenza VLP vaccines
produced in an egg-free cell culture system using recombinant technol-
ogy (Bright et al., 2008; Haynes et al., 2009; Kang et al., 2009). Inﬂuenza
VLP vaccines do not require handling of live inﬂuenza virus during the
development, manufacturing, or administration. In this study, we have
used a mouse model to investigate the immunogenicity of inﬂuenza
VLPs containing the WT H5 HA or mutant H5 HA with a deletion of the
multibasic amino-acid motif in the cleavage site as well as a recombinant
H5 HA protein vaccine after a single dose intramuscular vaccination.
Results
Production and characterization of H5 inﬂuenza VLPs
The highly virulent nature of HPAI viruses generates safety concerns
for use in manufacturing. Therefore, viruses containingmutated HA have
been previously generated for vaccine production purposes (GovorkovaFig. 1. Characterizationof inﬂuenzaH5VLPs. (A) Schematicdiagramof theWTandmutantH5H
mutantH5HA. (B)Westernblot of H5VLPs. RecombinantH5HAprotein (lane 1, 0.2 μg) andWT
were analyzed for incorporation of HA andNA (data not shown) bywestern blotting (1 μg/lane
of HA protein incorporation in VLPs. Threemicrograms ofWTH5VLPs were loaded in lane 1 an
respectively. The chemiluminescence signalswere digitized bydensitometer scanningof image
software (Alpha Innotech). (D) Trypsin cleavability of H5 HA incorporated into VLPs. WT (lane
0.1 μg of TPCK-treated trypsin for 2 h at 37 °C and cleaved form of proteins were conﬁrmed byet al., 2006; Lipatov et al., 2006; Subbarao et al., 2003). Recent studies
suggest that antibodies to the fusion peptide of the HA, adjacent to the
deleted amino acids, may contribute to protective immunity (Sui et al.,
2009). In this study, we compared the H5N1 inﬂuenza VLPs containing
the WT or mutant HA with a deletion of multibasic amino acids in the
cleavage site (Fig. 1A) using the rBV expression system. BothWT and del
H5VLPswere found toexhibit hemagglutination titers (HAU) in the range
of 2560 to 5120 (1 mg of VLPs in 1 ml PBS solution).
Incorporation of inﬂuenza virus proteins into VLPswas conﬁrmed by
western blotting (Fig. 1B). As we expected, a different cleavage pattern
of HA protein was observed between the WT and mutant form of HA.
Mutant del H5VLPs lacking the polybasic amino acid in the HA cleavage
site showed the precursor HA0 as the major HA form incorporated
(Fig. 1B Lane3). On the other hand, HA1, a cleaved HA product of
approximately 42 kDa, was the dominant protein in the WT H5 VLPs
(Fig. 1B Lane2) and recombinant H5 HA protein (Fig. 1B Lane1), both of
which were expressed in insect cells. The observation of the HA1
cleavage product in themutant H5 VLPs even as a minor band indicates
the presence of a protease like furin in insect cells (Stieneke-Grober
et al., 1992), which can cleave mutant H5 HA0 but much less efﬁciently
compared to the wild type H5 HA0. To determine the amount of HA
protein incorporated in H5 VLPs, we performed immunoblotting with
H5VLPs in comparisonwithH5HArecombinant proteins (100, 200, and
400 ng) as a reference standard (Fig. 1C). The chemiluminescence
intensity which represents the protein amount was measured by spot
densitometry to calculate the protein content based on densitometry
scanning (Fig. 1C). As a result, the amount of HA incorporated in 3 μg of
VLPs was estimated to be equivalent to 341 ng of HA recombinant
protein, representing approximately 11.4% of the total VLP proteins.
Finally, we determined the accessibility of trypsin to the H5 HA protein
in VLPs. As shown in Fig. 1D, both the WT (Fig. 1D Lane1 and 3) and
mutant H5 HA proteins (Fig. 1D Lane2 and 4) incorporated into VLPs
were similarly susceptible to trypsin-mediated cleavage.
These results indicate that both WT and mutant H5 HA proteins
incorporated into VLPs maintain conformational integrity. Also, theWT
H5 VLPs incorporated a cleaved form of HA dominantly as compared to
that of mutant H5 VLPs that contain predominantly a precursor form of
HA. Thus, insect cells can effectively process the WT H5 HA proteins
containing multiple basic amino acids at the cleavage site.Agenes used for preparationofH5VLPs. Themultibasic amino acidmotifwasdeleted in the
(lane 2) ormutant (lane 3 and 4)H5VLPs puriﬁed by sucrose gradient ultracentrifugation
) using rabbit anti-HA antibody ormouse anti-M1 antibody. (C) Spot densitometry analysis
d three different amount of H5 rHA proteins (100, 200, and 400 ng) were in lane 2, 3, and 4
intensities onwestern blot. VLPs and recombinant proteinswerequantitated byAlphaview
1 and 3) and mutant (lane 2 and 4) H5 VLPs (1 μg/lane) were incubated without or with
western blotting.
Fig. 2. Kinetics of antibody responses after a single dose vaccination. Groups of mice
(n=9) were immunized by intramuscular injections with WT H5 VLPs containing 0.4
or 2.0 μg HA, or with the 0.4 or 2.0 μg of H5 HA recombinant protein vaccine. (A) H5 HA
speciﬁc IgG antibody titers by ELISA in sera at days 0, 8 and 14 (d0, d8, d14 respectively)
post a single dose vaccination. (B) H5 HA speciﬁc IgG antibody titers at days 28, 120 and
180 (d28, d120, and d180 respectively) post a single dose vaccination. (C) Titers of H5
HA speciﬁc IgG antibodies among different forms of vaccine. wtVLP: VLPs containing
the 0.4 μg of WT H5 HA, ΔVLP: VLPs containing 0.4 μg of the mutant H5 HA. Titers are
expressed as the highest fold dilution giving an optical density at 450 nm greater than
the mean value plus 3 standard deviations of naïve mouse serum samples. The asterisk
indicates a signiﬁcant difference between groups, *pb0.05, ** pb0.01, *** pb0.001.
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or VLPs
Conventional inactivated inﬂuenza vaccines are licensed for use by
intramuscular injection. To determine the immunogenicity of H5
antigens in a recombinant HA (rHA) or particulate VLP formulation,
groups of 9micewere intramuscularly immunizedwith a low(0.4 μgH5
HA) or high (2.0 μg H5HA) dose of rHA orWTH5VLPs. Serum antibody
responses induced after a single dose vaccine were evaluated at
different time points (days 8, 14, 28, 120 and 180) by ELISA coated
with the puriﬁed H5 HA protein antigen. As early as day 8 post
immunization, low but signiﬁcant levels of H5 HA speciﬁc antibodies
were induced in the groups of VLP immunized mice (Fig. 2A, pb0.05
between the samedose of rHA and VLP groups). The levels of antibodies
gradually increased up to day 120 post vaccination for high dose VLP
groups (Fig. 2B, pb0.01), and were maintained for at least 6 months.
In contrast, after a single dose immunization with recombinant H5
HA protein, no signiﬁcant levels of antibodies were observed until day
28 post immunization even in the high dose HA group (2.0 μg of HA). At
days 120 and 180 post vaccination, antibodies were detected in rHA
immunizedgroupsbut the levelswere signiﬁcantly lower than even low
dose VLP immunized groups (Fig. 2B, pb0.05). Mutant VLP vaccinated
mice also showed signiﬁcantly higher levels of antibodies than those in
recombinant H5 HA groups (Fig. 2C, pb0.001) and the antibody
induction kinetics were similar to those observed in the WT H5 VLPs
(Fig. 2C). Therefore, the results indicate that both WT and mutant H5
VLP vaccines were similarly superior to the recombinant H5HA vaccine
in inducing higher antibody responses with faster kinetics.
Antibody isotypes and hemagglutination inhibition titers
To further characterize the antibody responses, we determined the
pattern of isotypes induced by VLP or recombinant protein vaccina-
tion. IgG1 antibody, which reﬂects a T helper type 2 (Th2) biased
response, was found to be the dominant subclass in the high dose
soluble protein vaccination group when analyzed at day 120 post
vaccination (Fig. 3A). In contrast, the low dose VLP group induced
IgG2a and IgG2b antibodies predominantly at days 28 and 120 post
vaccination, indicating Th1 biased responses (Figs. 3B and C). The high
dose VLP vaccination induced not only IgG2a and IgG2b antibodies but
also the IgG1 subclass, representing both Th1 and Th2 immune
responses (Fig. 3D). The kinetic analysis of isotypes showed that VLP
vaccines induced IgG2a isotype antibody at an earlier time point than
other subclasses (Fig. 3B). Taken together, the results show that VLP
vaccines elicited robust and sustainable antibody responses. Also, the
types of vaccines (VLP versus recombinant form) as well as doses of
vaccines affected the pattern and kinetics of isotype antibody
responses.
To assess the induction of functional antibodies by each vaccine,
we determined the hemagglutination inhibition (HI) titers by
measuring the ability of serum samples to inhibit agglutination of
horse erythrocytes (Gillim-Ross and Subbarao, 2006). Sera from mice
immunized with recombinant H5 HA vaccines regardless of doses
showed only background levels of HI titers, similar to serum samples
from naïve mice (Fig. 4). Low doses (0.4 μg HA) of bothWT and del H5
VLP vaccines elicited meaningful HI titers of 40. High doses of H5 VLP
vaccines elicited HI titers of 80, an average 2 fold increase. Therefore,
presentation of H5 HA on VLPs was likely to have displayed HA in a
more immunogenic form and induced higher levels of functional
antibodies compared to the recombinant HA protein vaccine.
Protective efﬁcacy of the H5N1 inﬂuenza VLP vaccine in mice
The protective efﬁcacy of recombinant H5 HA and VLP vaccines was
assessed at 6 months after a single dose vaccination. Immunizedmice in
groups of 6 were intranasally challenged with 50 MLD50 of WT H5N1inﬂuenza virus (VN/04) and their health status monitored daily for
14 days. As shown in Fig. 5A, all groups that received a single dose of
either wild type or mutant H5 VLPs were 100% protected from lethal
challenge. No signiﬁcant body weight loss was observed in mice
immunizedwith eitherWTor del VLPs even containing a lowdoseof HA
Fig. 3. Kinetics of isotype antibody responses. (A) IgG1, (B) IgG2a, (C), IgG2b, and (D) sum of IgG2a/IgG1 at days 120. Groups of mice (n=9) immunized with a single dose are the
same as described in the legend of Fig. 2. IgG2a and IgG1 isotype titers were determined by quantitative ELISA (average±S.D.) of 1:100 diluted serum samples.
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protein or naïve infected mice rapidly lost body weight and died or had
to be euthanized because of their severe clinical symptoms on days 8 to
10 post challenge (Figs. 5A and B).Fig. 4. Hemagglutination inhibition (HI) titers. Serum samples were collected at
4 months after a single dose vaccination and HI titers were determined by standard
methods using 4 HA units of inactivated reassortant H5N1 virus (rg H5N1) and 1%
horse erythrocyte suspension. rHA, recombinant H5 HA protein;WTVLP, inﬂuenza VLPs
containing H5 WT HA; ΔVLP, inﬂuenza VLPs containing H5 mutant HA. Parenthesis
indicates the amount of HA protein used per mouse. Mock, a mock control group
immunized with PBS buffer.We also determined virus titers in lung, spleen and brain of the
challenged mice on day 4 post infection. The lung viral titers of mice
immunized with 2.0 μg of WT H5 VLPs were approximately 600-fold
lower than that of the naïve control. Importantly, lungviral titers inmice
immunized with the high dose of mutant H5 VLPs were below the
detection limit (Fig. 6). The lung viral titers inmice immunizedwith the
low dose of WT or mutant H5 VLPs were lower by 60 or 10 fold
compared to the naïve control group, respectively. Challenge virus was
detected in the brain in one of the recombinant HA vaccinated and
control mice. However, therewas no viral spread to any other organs in
VLP immunized mice (Fig. 6).
Inﬂuenza virus speciﬁc antibody secreting cell (ASC) responses in
bone marrow
Since a single intramuscular vaccinationwith inﬂuenza VLP vaccines
induced long term protective immunity, we wanted to determine the
levels of antibody secreting cells in the bonemarrowwhere long-lasting
plasma cells reside. To study antibody responses of the plasma and
memory B cells generated by vaccination as diagrammed in Fig. 7, mice
(n=3) immunized intramuscularly once with recombinant H5 HA or
VLPs 6 month earlier were sacriﬁced or were exposed to the
corresponding vaccine (2 μg recombinant HA or 0.4 μg mutant or wt
H5 HA VLPs) via the same route of delivery 6 days earlier prior to
sacriﬁce. Bonemarrow cells were cultured for 1 to 5 days in the absence
of in vitro antigenic stimulation (Fig. 8). Ex vivo culture supernatants
were harvested at days 1 and 5, and the H5 HA speciﬁc IgG levels were
measured by ELISA using the recombinant H5 HA as a coating antigen.
Fig. 5. Protection against wild type inﬂuenza A/Viet Nam/1203/04 (H5N1) virus challenge by a single dose vaccination. Groups of vaccinated mice and a mock control (PBS) were
intranasally challengedwith a lethal dose (50×MLD50) of H5N1 inﬂuenza virus (n=6 per group). (A) Bodyweight changes. (B) Survival rate. The percent of bodyweight loss calculated
from the initial bodyweight taken at day 0wasmonitored for 14 days. Data are the average from6 individualmice. rHA, recombinant H5HAprotein;wtVLP, inﬂuenza VLPs containingH5
WT HA; ΔVLP, inﬂuenza VLPs containing H5 mutant HA. Mock, a mock control group injected with PBS buffer.
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cell culture media were detected even 6 month after a single VLP
vaccination, but not with recombinant H5 HA vaccination (stripe bar
and Table 1). Signiﬁcant increases were observed in the levels of
secreted antibodies from the groupof VLP vaccinatedmice that received
in vivo the VLP antigenic challenge 6 days prior to sacriﬁce (Table 1). In
contrast, after treatment with in vivo recombinant HA antigenic
challenge, the recombinant H5 HA immunized mice did not show
such increases in the ex vivo antibody production.
To determine the continued production of antibodies by plasma
cells, the cultures were extended to 5 days. The IgG antibodies
accumulated signiﬁcantly in culture supernatants in both WT and
mutant H5 VLP vaccination groups but only negligible amounts of
antibodies were secreted into the culture supernatants in the
recombinant H5 HA vaccinated group during the 5 days of culture
(Fig. 8B stripe and closed bar and Table 1). Also, neither detectable levelsFig. 6. Effective control of viral replication by a single dose VLP vaccination. Groups of
mice that received a single intramuscular vaccination with recombinant H5 HA protein
or H5 VLPs were intranasally infected with inﬂuenza A/Viet Nam/1203/04 (H5N1)
virus (50×MLD50) and sacriﬁced on day 4 post challenge (n=3). Spleen, lung and
brain tissue samples were harvested from individual mice and the homogenates were
used for plaque assay to determine virus titers. Data are represented by the mean virus
titer (plaque forming unit [pfu] per ml of homogenate) with standard error of mean
(SEM). The dashed line indicates the limit of detection (1.7 log10 pfu/ml). * Virus was
isolated from one out of three mice.nor cumulative effectswere observed in the unvaccinated control group
with an exposure to the in vivo VLP antigenic challenge 6 days earlier
(Fig. 8 open bar, Table 1). These results provide evidence that VLPs are
superior to the recombinant HA vaccine in generating long-lived
antibody secreting plasma cells in bone marrow. Also, these results
indicate that VLP vaccination can induce rapid increases in antibody
secreting plasma cells in bone marrow within a time frame of 6 days
post in vivo antigen exposure.Antibody secreting and recall B cell responses in spleen induced by
VLP vaccination
In order to evaluate the inﬂuenza virus speciﬁc memory B cell
responses induced at 6 months after a single dose of VLP intramuscular
vaccination, we performed a plasma and memory B cell assay with
splenocytes with or without exposure to in vivo antigenic challenge
followed by the presence or absence of in vitro exposure to inactivated
H5 virus (Fig. 7). During the ﬁrst day of ex vivo culture of splenocytes
collected from mice vaccinated with recombinant HA or VLP vaccine
without in vivo antigenic challenge, the levels of antibodies in the
culture supernatantswere negligible regardless of antigenic stimulation
during in vitro cultures (Figs. 9A and C stripe bar). Even after 5 days of
extended culture without the antigenic stimulation, the levels of
antibody production ex vivo were not signiﬁcant except for slight
increases in the WT VLP immunized group (Table 2).Fig. 7. Experimental design to determine antibody secreting plasma cells and recall
immune responses. To evaluate long-lived plasma and memory B cells, groups of mice
were intramuscularly vaccinated with a single dose. Six months later a set of the same
groups was intramuscularly re-immunized with the same vaccine antigen (Ag) 6 days
earlier before sacriﬁce to determine in vivo recall immune responses (vaccine +/− Ag.
rechallenge). In vitro Ag stimulation indicates in vitro antigen exposure with inactivated
virus to activate pre-existing memory B cells.
Fig. 8. In vitro antibody production during bone marrow cell culture. Bone marrow cells isolated from vaccinated mice with or without in vivo vaccine Ag. rechallenge were placed on
a 96-well plate in quadruplicate and incubated for 5 days without in vitro stimulation. Culture supernatants were harvested on day 1 (A) and day 5 (B) post culture, and inﬂuenza
speciﬁc IgG levels in culture supernatants (2× diluted) were determined by ELISA. Groups of mice (n=3) were intramuscularly vaccinated with recombinant H5 HA (rHA, 2 μg HA),
inﬂuenza VLPs containingWT H5 HA (wtVLP, 2 μg HA), or inﬂuenza VLPs containing mutant H5 HA (ΔVLP, 2 μg HA) 6 months ago. Control (no pre vaccination), groups of naïve mice
(n=3) intramuscularly injected with the corresponding vaccine indicated (2 μg of rHA, wtVLP or ΔVLP containing 0.4 μg HA) 6 days earlier prior to sacriﬁce. Vaccine: Vaccinated
mice (n=3) without in vivo antigenic challenge. Vaccine+Ag. rechallenge, groups of vaccinated mice (n=3) intramuscularly 6 months earlier were re-immunized with the same
vaccine (2 μg of rHA, WTVLP or delVLP containing 0.4 μg HA) 6 days prior to sacriﬁce.
170 J.-M. Song et al. / Virology 405 (2010) 165–175Importantly, after antigenic stimulation in vitrowith inactivated H5
virus during the 5-day extended culture, the levels of antibodies
secreted into the culture supernatantswere signiﬁcantly increasedup to
16 to 18 fold in the groups vaccinated with mutant or WT VLPs
compared to those during the ﬁrst day culture (Fig. 9D stripe bar and
Table 3). TheWTVLP groupwasmoderately higher than themutant VLP
group (Fig. 9D stripebar, Table 3). These results provide evidence for the
generation of long-lived memory B cells by VLP vaccination, which can
differentiate into antibody secreting plasma cells by in vitro antigenic
stimulation.
To further characterize thememory B cells generated by vaccination,
recombinant HA or VLP vaccinated mice were antigenically re-
stimulated in vivo with the corresponding type of vaccines (vaccine+
Ag. rechallenge). Signiﬁcant levels of antibodies secreted into the
culture supernatants were detected in VLP vaccinated groups, with
increases of 6 to 10 fold after 1 day ex vivo culture (Fig. 9A and Table 2,
stripe versus closed bar), but not in the recombinant HA vaccine group
(Fig. 9A). Noticeably, after in vitro antigenic stimulationwith inactivated
H5 virus, the levels of IgG antibodies secreted into the culture
supernatants were increased by approximately 2.5 to 4 fold compared
to those without the in vitro antigenic stimulation during 5 days ex vivo
culture (Figs. 9B and D closed bar and Tables 2 and 3). It was noted that
the mutant H5 VLP group showed a trend of higher responses after in
vivo antigenic challenge (Fig. 9B and Table 2), which might have
contributed to more efﬁcient lung viral control in this mutant H5 VLP
group as observed in Fig. 6. These results suggest that inﬂuenzamemory
B cells induced by VLP vaccination, but not by the recombinant HA
vaccine, can rapidly respond to antigenic challenge in vivo, differenti-
ating to antibody secreting plasma cells in the spleen and eventually
trafﬁcking to the bone marrow.Table 1
IgG titers induced by plasma cell in BM during ex vivo culturea.
Days of
incubation
Recombinant HA wtVLP
Control Vaccine Vacc.+Ag.
rechallenge
Control Vaccine
day 1 b106±26.3 84.2±24.6 122±31.1 56.1±19.9 364±
day 5 165±32.9 334±189 576±194 56.8±5.60 1070±
a IgG titers induced by plasma cell determined with quantitative ELISA.
b Values are means±S.D. (ng/ml) of four independent ex vivo culture plate wells. Cont
Vaccine: Vaccinated mice (n=3) without in vivo antigenic challenge. Vacc.+Ag. rechallengeCellular immune responses induced by VLP vaccination
To investigate the cellular immune responses induced by VLP
vaccination, we determined IL-4 and IFN-γ secreting splenocytes by
ELISPOT. Splenocytes were isolated from immunized mice after
6 months vaccination and stimulated with a peptide pool of HA1 or
HA2 subunit derived from A/Thailand/16/04 (H5N1) inﬂuenza virus.
Without the in vivo antigenic exposure, cytokine-secreting splenocytes
were detected at higher levels than those in naïve controls, but their
levels were low (Fig. 10). After in vivo antigenic challenge with the
corresponding vaccine antigen 6 days prior to sacriﬁce, higher levels of
IL-4 secreting cells were observed upon the stimulation with the HA1
peptidepool in the recombinantprotein immunized group than those in
the VLP group (Fig. 10A). In contrast to IL-4, the levels of IFN-γ secreting
splenocytes in the VLP groupwere signiﬁcantly higher than those in the
recombinant H5 HA group (Fig. 10B). Taken together, these results
indicate that the recombinant HA vaccines are likely to induce Th2 type
responses as represented by the IL-4 cytokine production. The VLP
vaccines induce both Th1 and Th2 type immune responses with
preferences of the Th1 type immune responses as evidenced by higher
levels of IFN-γ production.
Discussion
Two doses of inﬂuenza vaccine given four weeks apart are
recommended to induce protective immunity particularly for children,
who are more likely to be immunologically naïve. The majority of the
population is also immunologically naïve to the HA glycoprotein antigens
from pandemic potential H5N1 inﬂuenza viruses. It would therefore be
highly desirable to develop an effective single dose vaccination. In thisΔVLP None
Vacc.+Ag.
rechallenge
Control Vaccine Vacc.+Ag.
rechallenge
Naïve
98.3 1290±253 50.7±16.3 183±73.1 1670±402 40.0±8.5
286 3810±57 193±29.5 808±433 4150±651 84.7±6.1
rol: Naïve mice (n=3) with in vivo antigenic challenge 6 days earlier before sacriﬁce.
: Vaccinated mice (n=3) with in vivo antigenic challenge 6 days earlier before sacriﬁce.
Fig. 9. In vitro antibody production by spleen cell culture. Groups of mice are the same as described in the legend of Fig. 8. Splenocytes were incubated in the absence (A, B) or in the
presence (C, D) of inactivated A/VN/04 virus coated on the 96well culture plates for in vitro stimulation and incubated for 5 days. Culture supernatants were harvested at day 1 (A, C)
and day 5 culture (B, D), and inﬂuenza speciﬁc IgG levels were determined by ELISA.
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correlates including the detailed kinetics of antibody induction, protective
potential, and the generation of long-lived plasma and memory B cell
immune responses after a single dose intramuscular vaccination with H5
VLPs containing the wild type or mutant H5 HA, or a subunit vaccine
consisting of recombinant H5 HA protein. H5 HA VLPs were found to be
superior to the recombinant H5 HA protein in inducing binding and
functional antibodies, and in providing protective immunity as well as in
generating plasma and memory B cell responses.
Many inﬂuenza vaccine strains especially for vaccines against highly
pathogenic avian inﬂuenza viruses are generated as reassortants using
reverse genetics technology (Govorkova et al., 2006; Lipatov et al., 2006;
Nicolson et al., 2005; Subbarao et al., 2003; Webby et al., 2004). The HA
genes in the HPAI vaccines are modiﬁed to remove the highly cleavable
multibasic amino-acid motif, a known virulence determinant. However,
the effect of thepresence of thismultibasic amino-acidmotif in theWTH5Table 2
IgG titers induced by ASC in spleen during ex vivo culturea.
Days of
incubation
Recombinant HA wtVLP
Control Vaccine Vacc.+Ag.
rechallenge
Control Vaccine
day 1 b88.9±33.2 98.0±24.2 95.1±19.4 70.7±21.4 83.3±2
day 5 103±27.3 76.8±28.1 129±43.4 99.1±64.9 269±1
a IgG titers induced by plasma cell determined with quantitative ELISA.
b Values are means±S.D. (ng/ml) of four independent ex vivo culture plate wells. Contr
Vaccine: Vaccinated mice (n=3) without in vivo antigenic challenge. Vacc.+Ag. rechallengeHA on inducing protective immune responses has not been well studied.
We produced VLPs containing either WT HA or a deletion mutant HA,
lacking the multibasic sequence, and compared their immunogenicities.
Themutant formofHApresented inanuncleavedprecursor conformation
on VLPs induced comparable immune responses as the WT form of HA
presented in an processed conformation on VLPs and possibly provided
superior protection as evidenced by effective virus clearance. Thus, this
study provides the ﬁrst evidence supporting the rationale for generating
pandemic vaccines with a mutated HA cleavage site.
Vaccination consisting of formalin-inactivated whole virus particles
that were ﬁrst licensed in 1945 in the U.S. was often associated with a
relatively high incidence of adverse events particularly among children
(Nicholsonet al., 1979;Wright et al., 1977). Since then,detergent split or
ether-disrupted vaccines or puriﬁed viral subunit HA and NA proteins
have been more commonly used for intramuscular vaccination.
Inﬂuenza VLPs have been suggested as a promising alternativeΔVLP None
Vacc.+Ag.
rechallenge
Control Vaccine Vacc.+Ag.
rechallenge
Naïve
5.1 352±139 8.4±11.9 67.8±19.7 680±378 76.2±16.1
65 535±199 61.3±30.8 63.0±29.6 973±132 76.1±39.0
ol: Naïve mice (n=3) with in vivo antigenic challenge 6 days earlier before sacriﬁce.
: Vaccinated mice (n=3) with in vivo antigenic challenge 6 days earlier before sacriﬁce.
Table 3
IgG titers induced by ASC in spleen during ex vivo culture with in vitro antigen stimulationa.
Days of
incubation
Recombinant HA wtVLP ΔVLP None
Control Vaccine Vacc.+Ag.
rechallenge
Control Vaccine Vacc.+Ag.
rechallenge
Control Vaccine Vacc.+Ag.
rechallenge
Naïve
day 1 b157±41.2 92.6±22.2 101±38.1 78.2±30.4 116±41.6 374±147 73.6±33.0 83.0±37.2 475±224 117±32.5
day 5 74.8±42.8 134±120 915±531 60.5±20.1 2170±500 3100±370 84.2±50.6 1320±224 2470±311 67.5±11.1
a IgG titers induced by in vitro antigen stimulated ASC cell determined with quantitative ELISA.
b Values are means±S.D. (ng/ml) of four independent ex vivo culture plate wells. Control: Naïve mice (n=3) with in vivo antigenic challenge 6 days earlier before sacriﬁce.
Vaccine: Vaccinated mice (n=3) without in vivo antigenic challenge. Vacc.+Ag. rechallenge: Vaccinated mice (n=3) with in vivo antigenic challenge 6 days earlier before sacriﬁce.
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(Bright et al., 2008; Haynes et al., 2009; Kang et al., 2009). Also, Bright
et al. demonstrated that seasonal inﬂuenza VLPs induced broader
immune responses compared to inactivated whole inﬂuenza virus
vaccine (Bright et al., 2007). In these previous studies, prime and boost
immunizationswere applied for inducing protective immune responses
against avian inﬂuenza viruses, which is a common vaccination regimen
in using animal models. Considering that most individuals in the
population are naïve to avian or pandemic potential strains, protection
with a single dose vaccination in a naïve immune conditionwould have
signiﬁcant implications for public health. The present study provides
insight into the kinetics and types of immune responses contributing to
protection after a single dose VLP vaccination as well as potential
mechanisms explaining low immunogenicity of soluble subunit vaccine.
Compared to the recombinant H5 HA vaccine, the H5 VLPs induced
signiﬁcantly higher levels of IgG antibody responses with faster kinetics.
Vaccinationwith the recombinant H5HAprotein showed a delayed type
of antibody responses until day 28 post vaccination. Also, the IgG1
antibody was found to be a major isotype, which was observed in the
high dose H5 HA group (2 μg HA) only at a later time point. In contrast,
both low and high doses of H5 VLP vaccines showed induction of IgG2a
and IgG2b isotypes as early as day 8 post vaccination. These observations
suggest that the VLP vaccines stimulate the host immune system to
initiate adaptive immunity byadifferentmechanismcompared to thatof
the recombinant antigens. In supporting this idea, we recently observed
that inﬂuenzaVLPswere immunogenic even in CD4T cell deﬁcientmice,
whereas, the recombinant HA protein was not able to induce antibody
responses in the absence of CD4 T cells (Kang et al., unpublished data).
Therefore, vaccines designed to mimic the virion structure as is the caseFig. 10. Cellular recall immune responses after VLP vaccination. The cellular immune responses
immunizedmice (n=3)with a single dose of vaccine 6 months earlier (single) or a single dose
sacriﬁce (Ag. rechallenge). Splenocytes were incubated on the IL4 or IFN-γ capture antibody co
inﬂuenza A/Thailand/16/04 (H5N1) virus which has over 99% homology to A/VN/04 HA. Aft
producing cells were counted. VLP single, Single vaccination withWT H5 VLPs; rHA single, sing
mice received a boost immunizationwithWTH5VLPs 6 days earlier prior to sacriﬁce; rHA+Ag
HA protein 6 days earlier prior to sacriﬁce. Statistical signiﬁcance **pb0.01, ***pb0.001.with VLPs provide an approach to improve vaccine efﬁcacy while
retaining the safety of a recombinant protein vaccine.
The type of the immune response induced by vaccines is also
important for protection. Infection by inﬂuenza virus or other viruses
induces IgG2a dominantly in mice (IgG2c in C57BL/6 mice) (Coutelier
et al., 1987; Fazekas et al., 1994). IgG2a antibody interacts efﬁcientlywith
complement and Fc receptors by virtue of its Fc domain properties
(Gessner et al., 1998; Heusser et al., 1977; Huber et al., 2006; Neuberger
and Rajewsky, 1981 ). Therefore, induction of IgG2a antibody by VLP
vaccination is considered to signiﬁcantly contribute to viral clearance,
probably via activation of the complement system, stimulation of
antibody-dependent cellular cytoxicity and clearance of opsonized virus
by macrophages (Huber et al., 2001; Jayasekera et al., 2007;
Mozdzanowska et al., 2006). The protective role of IgG2a antibody is
further supported by a recent study demonstrating that IgG2a induced by
vaccinationwithviral repliconparticleswas signiﬁcantlymoreeffective in
protection with enhanced viral clearance against lethal challenge than
IgG1 antibodies induced by DNA vaccination (Huber et al., 2006).
Consistent with these previous studies, the recombinant H5 HA vaccine
groupwhich inducedpredominantly an IgG1 isotype response at a similar
level to the high dose VLP group was not effective in controlling viral
replication as this group showed lung viral titers as high as the naïve
control challenge group. In contrast, H5 VLP immunized mice that were
capable of inducing mainly IgG2a isotype had signiﬁcantly lower lung
viral titers by more than one hundred fold to below the detection limit.
Regarding the T cell responses, previous studies provided evidence
that Th1 cells are superior to Th2cells inprovidingprotection against viral
infection by secreting IFN-γ, stimulating B cells, and directing CD8+Tcell
mediated cytolysis (Bot et al., 1998;Moran et al., 1999; Swain et al., 2006;were assessed by cytokine ELISPOT assay with splenocytes isolated from intramuscularly
vaccination plus in vivo antigenic challenge with the same type of vaccine 6 days prior to
ated plates in the presence of an HA1 and HA2 peptide pool, as a stimulator, derived from
er 36 h incubation, the plates were developed with substrate, and IL4 and IFN-γ cytokine
le vaccination with the recombinant H5 HA protein; VLP+Ag. rechallenge, after 6 months
. rechallenge, after 6 monthsmice received a boost immunizationwith the recombinantH5
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generating T cells secreting INF-γ indicating Th1 responses. In contrast,
recombinant HA vaccination induced T cells secreting IL-4 cytokine
representing Th2 type responses, which was not a protective response
since all mice in this group died after challenge. One or two immuniza-
tions with the H5 HA protein (3 μg HA, A/Indonesia/05/2005) were
reported to induce protection against lethal infection although mice
showed a loss in bodyweight and protective immune correlateswere not
identiﬁed (Bright et al., 2008). There are many factors which could be
involved indifferent results including thevaccine strain (A/VietnamvsA/
Indonesia) and dose, challenge virus strain (wild type vs reassortant) and
dose (50LD50 vs 10LD50), and timing of challenge infection (6 months vs
5 weeks post vaccination). Nevertheless, the current study clearly
indicates that inﬂuenza VLPs are an advantageous format of vaccine
inducing predominantly IgG2a isotype antibodies as well as Th1 type
cytokines such as IFN-γ, both of which are contributing to inducing
protective immunity.
Long-term serumantibodies aremaintained by plasma cells residing
in the bone marrow and spontaneously secreting antibodies into the
bloodstream (Slifka and Ahmed, 1996; Slifka et al., 1998; Slifka et al.,
1995). During the differentiation and development of B cells in the
germinal centers upon antigen exposure, memory B cells are generated
(Crotty et al., 2003; Kalia et al., 2006). Previously, prime and boost
intranasal immunizations with H5 VLPs were shown to induce plasma
and memory B cells in mice (Kang et al., 2009). In the present study to
better understand the long-lasting protective immunity after a single
intramuscular vaccination, the recombinant HA protein and VLP
vaccineswere compared.Weobserved that the recombinant H5protein
vaccine exhibited a signiﬁcant limitation in generating both plasma cells
in bone marrow and rapidly responding memory B cells in spleen
compared to the VLP vaccine. In clinical studies, high dose and
prime-boost immunizations with recombinant or conventional H5
vaccines were required, indicating their low immunogenicity (Bresson
et al., 2006; Lin et al., 2006; Nicholson et al., 2001; Treanor et al., 2006;
Treanor et al., 2001). Our study provides evidence for superior
immunogenicity of inﬂuenza VLPs to recombinant H5 protein based
subunit vaccine. It is speculated that inﬂuenza VLPs are an effective
immunogen in stimulating innate immune cells particularly dendritic
cells, a potent antigen presenting cells. A vaccine form capable of
strongly activating pathogen recognition receptors such as Toll-like
receptors on dendritic cells has been suggested to effectively induce
adaptive immunity including Th1 type immune responses (Pulendran,
2004; Pulendran and Ahmed, 2006). Viruses themselves are known to
induce strong B cell and cytotoxic T cell responses, while puriﬁed
recombinant antigens require an adjuvant to induce cellular immune
responses (Bachmann et al., 1998). Thus, alternatively, VLPs mimic
viruses in structure and morphology, and present HA molecules in a
highly structured repetitive array, which might allow efﬁcient cross-
linking of B cell receptors (Bachmann and Zinkernagel, 1996) However,
the underlying mechanisms remain to be determined. Therefore, VLPs
appear to be a promising approach for developing a vaccine that
effectively generates memory B cells that rapidly differentiate into
antibody secreting plasma cells upon antigenic stimulation, thus,
contributing to long-term protective immunity.
In conclusion, a single intramuscular administration of H5 VLPs, but
not of a recombinant H5 HA protein, provided complete protection
against lethal challenge infection. The H5 VLP vaccine was found to be
more effective in inducing Th1 type immune responses including IgG2a
and IFN-γ cytokine-secreting T cells aswell as in generating plasma and
memory B cells contributing to protection after a single intramuscular
vaccination. Therefore, inﬂuenza VLPs will offer signiﬁcant advantages
for vaccination particularly if a pandemic occurs. Considering the
current platforms of approved vaccines, it is important to investigate
detailed comparative immunogenicity and protective efﬁcacy of H5
VLPs in comparison with inactivated whole virus and attenuated live
H5N1 vaccines.Materials and methods
Cells, virus, and reagents
Spodoptera frugiperda sf9 insect cells were purchased from the
American Type Culture Collection (ATCC, CRL-1711) and maintained in
SF900-II SFM medium at 27 °C incubator. Sf9 insect cells were used for
production of recombinant baculoviruses (rBVs) and VLPs. Madin–Darby
canine kidney (MDCK) cells for viral titrationwere purchased from ATCC
and cultured inDulbecco'sModiﬁcation of Eagle'sMedium (DMEM)with
10% fetal bovine serum at 37 °C, 5% CO2 conditioned incubator. The WT
virus used for challenge studies was derived by reverse genetics from
HPAI A/Viet Nam/1203/04 (VN/04) H5N1 virus isolated from a fatal
human infection (Sui et al., 2009). Vaccine candidate virus rgΔH5N1
containing the multibasic amino acid deletion in HA gene and the wt NA
gene fromVN/04 and internal protein-coding genes fromA/Puerto Rico/
8/34 (PR/8/34)was reported previously (Donis, 2005;Wan et al., 2008).
The virus was inactivated as described (Kang et al., 2009) and used as an
H5 viral antigen for in vivo and in vitro antigenic challenge studies. All
workwith live H5N1 viruswas performed in bio-safety level 3 facilities at
the Centers for Disease Control and Prevention. Puriﬁed recombinant H5
HAprotein thatwas produced using a baculovirus expression systemwas
obtained from the NIH Biodefense and Emerging Infections Research
Resources Repository (NIAID, NIH) and used for vaccination. The VN/04
H5HA protein expressed inmammalian cells (293T cells) by transfection
was puriﬁed and used for an ELISA antigen.Preparation of H5 VLPs
Inﬂuenza H5 VLPs were generated and puriﬁed by following a
procedure previously described (Kang et al., 2009; Quan et al., 2007). To
generate the rBVs expressing inﬂuenza proteins, M1, and WT or
multibasic amino acid deleted (del or Δ) HA, genes from inﬂuenza VN/
04 virus were cloned into Bacmid (Invitrogen, Carlsbad, CA). Lipofectin
mixed with 2 μg of Bacmid was used for plasmid transfection with sf9
insect cells and recombinant baculoviruses were generated according to
the manufacturer's instruction. rBvs expressing HA and M1 protein were
co-infected into sf9 insect cells to produce H5 VLPs. At 3 days post
infection, the infected cell culture supernatants were clariﬁed by
centrifugationand thenwere concentratedbyhollowﬁberbasedﬁltration
using Quixstand (GE Healthcare, Waukesha, WI). Sucrose gradient
ultracentrifugation with layers of 20%, 30% and 60% (wt/vol) was carried
for puriﬁcation of VLPs at 28,000×g for 60 min.WT anddel-H5VLPswere
mainly puriﬁed from a band between 30 and 60% sucrose gradient.Characterization of H5 VLPs
The morphology of VLPs was examined by electron microscopy as
described (Quan et al., 2007). Expression of inﬂuenza proteins in VLPs
was analyzed by SDS-PAGEusing12%polyacrylamidegelswithGel code
blue staining solution (Thermo) and by western blotting using rabbit
anti-HA polyclonal antibodies (ProSci, Poway, CA) or mouse anti-M1
antibody (Serotec, Raleigh, NC) followed by detection with horseradish
peroxidase (HRP)-conjugated goat anti-rabbit or mouse IgG (South-
ernbiotech, Birmingham, AL). To quantitate the incorporating inﬂuenza
proteins in VLP, the total proteins of VLP and puriﬁed recombinant HA
were measured by DC protein assay kit (Bio-Rad, Irvine, CA) and
normalized to 1 μg/μl of total protein concentration. Densitometer
scanning of the HA protein bandwas performed using a Fluorchem FC2
imaging system (Alpha Innotech, San Leandro, CA) and the data
analyzed using Alphaview software (Alpha Innotech). Conformational
integrity and biological activity of HA protein on VLPs were determined
by trypsin cleavability and hemagglutination assays as previously
described (Kang et al., 2009).
174 J.-M. Song et al. / Virology 405 (2010) 165–175Immunization and challenge
Six to eight-week-old female BALB/cmice (Charles River,Wilmington,
MA) were housed in the animal facility of Emory University and all
experiments were carried out following the approved IACUC protocol.
Groups of mice (n=9) were given an intramuscular (i.m.) injection with
50 μl PBS solutioncontaining0.4 μgor2.0 μgbasedonHAcontentof either
recombinantHA,WTordelH5VLPs. Immunizedor PBS controlmicewere
challengedwith 50 fold of 50%mouse lethal doses (50MLD50) ofWTVN/
04virus. Challengedmiceweremonitoreddaily for disease signs andbody
weight changes for 2 weeks. All challenge experiments with VN/04 virus
were performed under the enhanced animal bio-safety level 3 facilities in
the Centers for Disease Control and Prevention.
To investigate plasma andmemory response, additional mice were
allotted into another 3 groups (n=3) and intramuscularly vaccinated
with 2 μg of recombinant HA, WT or del H5 VLPs containing 2 μg HA.
Virus titration
Infected mice were euthanized at 4 days post challenge. Lung, brain
and spleen were harvested and homogenized in 1 ml of PBS for virus
titration using a plaque assay in MDCK cells as previously described
(Kang et al., 2009). The limit of virus detectionwas 50 pfu (1.69 Log10) per
1 ml of organ homogenate.
Serologic test for determination of antibody responses
Peripheral blood samples were collected before and after immuni-
zation at different time points. Inﬂuenza virus speciﬁc antibody titers
were determined by ELISA as previously described (Quan et al., 2007).
Brieﬂy, 4 μg of inactivated inﬂuenza rgΔH5N1 virus or recombinant H5
HA protein produced in mammalian cells was used as a coating antigen
on the 96 well microtiter plates (Nunc, Rochester, NY) with overnight
incubation at 4 °C. The wells were washed three times with PBS
containing0.05%Tween20 (PBST) and blockedwith PBST containing3%
BSA for 2 h at 37 °C. Serially diluted serum samples were added and
incubated for 1 h at 37 °C then HRP-conjugated goat anti-mouse IgG,
IgG1, IgG2a and IgG2b were used as secondary antibodies and
O-phenylenediamine (OPD) as a substrator. To determine the antibody
titers, absorbance was read at 450 nm. Receptor destroying enzyme
(RDE) treated serum samples were used for hemagglutination
inhibition (HI) assay (Wakamiya et al., 1992). Brieﬂy, two fold serial
diluted serum samples (25 μl) were incubated with equal volumes RT)
for 30 min. After incubation, equal volume of 1% horse of inactivated
rgΔH5N1 virus (4HAU) at room temperature (erythrocytes was added
and incubated at RT for 1 h. The HI titer was expressed as the reciprocal
of thehighest dilution of the samples and thedetection limitwas20HAI.
ELISPOT for determination of T cell responses
Capture antibodies againstmouse IFN-γ and IL-4 cytokines (3 μg/ml
in coating buffer, BD Biosciences, San Diego, CA) were coated on the
Multi-screen 96 well plates (Millipore, Billerica, MA). Splenocytes
(1.0×106 cells/well) isolated from different vaccinated or control mice
were cultured on the platewith 100 μl of RPMI1640mediawith 10% FBS
with orwithoutHA1 orHA2 subunit peptide pool stimulator (10 μg/ml)
derived from A/Thailand/16/04 (H5N1) which is highly homologous
with VN/04 (Kang et al., 2009). After 36 h incubation, the plates were
washed with PBS and further incubated with biotinylated rat anti-
mouse IFN-γ or IL-4 (1 μg/ml in PBST with 5% FBS). After three
additional washes, HRP-conjugated streptavidin solution was added to
each well for 3 h at RT. The plates were washed and developed with
stable DAB (3, 3-Diaminobenzidine). The number of IFN-γ or IL-4
secreting T cells was counted using an ImmunoSpot ELISpot reader
(Cellular Technology, Shaker Heights, OH).Antibody secreting cell assay
Bone marrow and spleen derived single cell suspensions were
prepared at 6 months post vaccination with a single dose of VLPs or
recombinant vaccinewith or without antigen rechallenge 6 days before
sacriﬁce. Bonemarrow (0.5×106 cells/well) and spleen (1.0×106 cells/
well) cells were placed in 96 well culture plate with or without VN/04
inﬂuenza inactivated virus coating for in vitro antigen stimulation and
subjected to ex vivo cultures. Culture supernatants were harvested at
day 1 and 5 and levels of H5 HA speciﬁc antibodies in the culture
supernatants secreted by antibody secreting cells were determined
by ELISA.
Statistical analysis
To determine the statistical signiﬁcance, the Kaplan–Meier survival
analysis was performed using Graphpad PRISM. All experimental data
were recorded for individuals within groups unless speciﬁed. A
two-tailed Student's t-test was used when comparing two different
conditions. A p value less than 0.05 was considered to be signiﬁcant.
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